. Author manuscript; available in PMC: 2019 Jun 15.

Published in final edited form as: Am J Cardiol. 2018 Mar 16;121(12):1548–1551. doi: 10.1016/j.amjcard.2018.02.043

Table 2.

Demographics, comorbidities, and procedures by bridging use

	Bridging		P-value
	Yes (n = 86)	No (n = 254)
Mean Age (SD) (years)	67.0 (14.7)	67.5 (14.6)	0.746
Men	48 (56%)	184 (72%)	0.004
White	77 (90%)	233 (92%)	0.703
Black	4 (5%)	13 (5%)
Mean CHADS₂ (SD)	2.7 (1.3)	2.0 (1.0)	<0.001
Mean CHA₂DS₂-VASc (SD)	4.1 (1.8)	3.4 (1.4)	<0.001
Prior Stroke	33 (38%)	19 (8%)	<0.001
Mean HAS-BLED (SD)	1.5 (0.9)	1.3 (0.8)	0.065
Staff Making Anticoagulation Decision (% in row)
■ Cardiology	22 (18%)	104 (82%)	0.012
■ Gastroenterology	29 (35%)	54 (65%)
■ Primary Care Provider	31 (30%)	72 (70%)
■ Other	4 (15%)	23 (85%)
Staff Making Anticoagulation Decision (% in row)
■ Cardiology	22 (18%)	104 (82%)	0.011
■ Non-Cardiology	64 (30%)	150 (70%)
Esophagogastroduodenoscopy	24 (29%)	57 (23%)	0.340
Colonoscopy	62 (72%)	193 (77%)
Mechanical Valve (% in row)	9 (100%)	0 (0%)	n/a
• Aortic Mech Valve	7/7 (100%)	0/7 (0%)	n/a
• Mitral Mech Valve	2/2 (100%)	0/2 (0%)
Number of Antiplatelet Agents (% in row)
• None	54 (25%)	160 (75%)	0.722
• One	31 (25%)	93 (75%)
• Two	1 (50%)	1 (50%)

Note: Antiplatelet agents included aspirin, clopidogrel, prasugrel, and ticegrelor.